PDO Based Drug Sensitive Test in R/M SGC
NCT06686979 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2025-09-03
Summary
To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.
Conditions
- Salivary Gland Cancers
- Patient Derived Organoid
- Drug Sensitive Test in Vitro
Interventions
- OTHER
-
No Intervention: Observational Cohort
The patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
Sponsors & Collaborators
-
Shanghai Cancer Hospital, China
collaborator OTHER -
Eye & ENT Hospital of Fudan University
collaborator OTHER -
Dongfang Hospital Affiliated to Tongji University
collaborator OTHER -
Shandong Cancer Hospital and Institute
collaborator OTHER -
Qilu Hospital of Shandong University
collaborator OTHER -
Shandong Provincial Hospital
collaborator OTHER_GOV -
Hospital of Stomatology, Wuhan University
collaborator OTHER -
Second Affiliated Hospital, School of Medicine, Zhejiang University
collaborator OTHER -
Zhejiang University
collaborator OTHER -
Sir Run Run Shaw Hospital
collaborator OTHER -
Zhejiang Cancer Hospital
collaborator OTHER -
Shanghai Huangpu District Central Hospital
collaborator UNKNOWN -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
collaborator OTHER -
Wuhan TongJi Hospital
collaborator OTHER -
Zhongnan Hospital
collaborator OTHER -
Huashan Hospital
lead OTHER
Principal Investigators
-
Lai-ping Zhong, MD, PhD · Huashan Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-26
- Primary Completion
- 2026-11-30
- Completion
- 2028-11-30
Countries
- China
Study Locations
More Related Trials
-
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499 ·Status: RECRUITING ·Phase: PHASE2
-
Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC)
NCT07076693 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors
NCT02921984 ·Status: COMPLETED ·Phase: PHASE1
-
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT05978284 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
NCT05798793 ·Status: RECRUITING ·Phase: PHASE3
-
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
NCT06283719 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients
NCT02575547 ·Status: COMPLETED
-
Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer
NCT02937519 ·Status: UNKNOWN ·Phase: PHASE2
-
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
NCT07235319 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
NCT06130332 ·Status: RECRUITING ·Phase: PHASE2
-
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
NCT06363123 ·Status: RECRUITING
-
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
NCT04412616 ·Status: RECRUITING ·Phase: PHASE1
-
Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma
NCT00816816 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
NCT07248956 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
NCT06692491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clinical Study of SM3321 With Solid Tumors
NCT06087770 ·Status: RECRUITING ·Phase: PHASE1
-
Study of ZGGS34 in Participants With Advanced Solid Tumors
NCT07258121 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
NCT06861712 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
NCT05924256 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC
NCT02978196 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705 ·Status: RECRUITING ·Phase: PHASE2
-
Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative
NCT05774483 ·Status: RECRUITING ·Phase: NA
-
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
NCT06228079 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
NCT03734913 ·Status: UNKNOWN ·Phase: PHASE1
-
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
NCT04833257 ·Status: COMPLETED ·Phase: PHASE2